Details for Patent: 8,069,851

Which drugs does patent 8,069,851 protect, and when does it expire?

Patent 8,069,851 protects TOBI PODHALER and is included in one NDA.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 8,069,851

Title:	Aeorosolization apparatus with air inlet shield
Abstract:	An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aerosolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle.
Inventor(s):	Dunkley; Michael John (Nottingham, GB), Tuckwell; Jon David (Cambridgeshire, GB), Vernon-Harcourt; Edward William (Cambridge, GB), Shirgoankar; Sameer (London, GB)
Assignee:	Novartis AG (Basel, CH)
Application Number:	12/456,807
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form; Delivery; Device;

Drugs Protected by US Patent 8,069,851

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes			Y

International Family Members for US Patent 8,069,851

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	549051
Australia	2004229446
Canada	2520032
Cyprus	1113859
Denmark	1610850